GHR-2 (GHRP-2) dosage

GHR-2 (GHRP-2) injectable dosage

Reported injectable protocols use 100–300 mcg per administration, 2-3 times daily for 8-12 weeks. Another reported once-daily subcutaneous progression uses 100 mcg in weeks 1–2, 150 mcg in weeks 3–4 and 200 mcg from week 5, over an 8–16-week course. This is distinct from patterns with two or three administrations per day.[1][2][3][4][5][12]

GHRP-2, also known as pralmorelin, activates the ghrelin receptor and stimulates GH release. Appetite and endocrine effects are relevant when assessing tolerability.[1][2][3][6]

GHR-2 (GHRP-2) intranasal dosage

Reported-use amounts for GHR-2 (GHRP-2) are 100 mcg per administration, 2x daily, for approximately 4 wk.[11]

GHRP-2, also known as pralmorelin, activates the ghrelin receptor and stimulates GH release. Appetite and endocrine effects are relevant when assessing tolerability.[7][4][5][6][1][3][11]

GHR-2 (GHRP-2) oral dosage

A documented investigational oral amount is 900 mcg/kg twice daily for 12 months in children with growth-hormone deficiency. This pediatric, weight-based regimen does not define an adult oral dose.[8]

GHRP-2, also known as pralmorelin, activates the ghrelin receptor and stimulates GH release. Appetite and endocrine effects are relevant when assessing tolerability.[8][6][1][3]

Frequency and timing

Injections are commonly timed in the morning, before a workout or before bed, usually away from food. The nasal pattern lists morning and bedtime administration away from food; the oral preparation follows its separate twice-daily schedule.[1][2][3][4][5][11][8]

Cycle length and breaks

Injectable: 8-12 weeks. Intranasal: ~4 wk. Oral: 12 months. A standard break interval between courses is not established.[1][2][3][4][5][11][8]

Approval and product quality

GHR-2 (GHRP-2) is not an FDA-approved drug.[9][10]

Side effects and long-term safety

Appetite change, water retention, glucose and IGF-1 changes, and ACTH, cortisol or prolactin effects are relevant to ghrelin-receptor and GH-axis stimulation. Injectable product quality, pregnancy, active malignancy and sports restrictions also require attention.[1][2][3][9][10]

Route-specific dosing limits

Long-term unapproved GH-secretagogue use needs lab monitoring and careful exclusion of higher-risk contexts. Reported-use intranasal schedules and additional protocol patterns are not established human treatment regimens or approved product instructions.[1][2][3][9][10][12][11]